DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» UCB (company)
UCB (company)
UCB SA (Incorporated with Limited Liability in Belgium) As Issuer
Integrated Annual Report 2020
Dynavax Announces Full Enrollment of Phase II/III AIC Trial
Lamotrigine Orally Disintegrating Tablet
Portfolio of Investments
205836Orig1s000 205837Orig1s000 205838Orig1s000
Celltech, a Sound Strategic Acquisition Neutral
FORM 8-K PDL Biopharma, Inc
Schedule of Investments (Unaudited) Ishares MSCI EAFE International Index Fund March 31, 2021 (Percentages Shown Are Based on Net Assets)
2015 Annual Report PROFILE
Ceo of Biopharma Company Ucb to Chair Imi Governing Board
Report to Shareholders and Society Who We Are
2020 Annual Report
FACTSHEET - AS of 24-Sep-2021 Solactive GBS Belgium Large & Mid Cap Index TR
List of Running Issuance Programs (03/09/2021)
Euronext Brussels 10 Largest Market Caps
UCB Integrated Annual Report 2019
Transparency in Corporate Reporting
Top View
Amphetamine Orally Disintegrating Tablets: Another Option for the Treatment of Attention Deficit Hyperactivity Disorder Marcia L
2006 Re and So
For Immediate Release Ucb Pharma Enters Into
Press Release
Adding Value with PI at Umicore
17 Benelux-Aandelen Voor De Start Van Het Nieuwe Beursjaar
Euro Stoxx® Multi Premia Index
UCB Selects Genpact to Manage Its Global Finance & Accounting Operations
Activity Report
2019 Belgium Spencer Stuart Board Index Header (Section Title) — (Remove When Section Header Present)
Transparency Notification UCB SA/NV • Notification Referring to Situation on 17 January 2020 • Threshold Crossed: 3% • Latest Holding: 2.95%
Prospectus 30/11/2018
View Annual Report
Portfolio of Investments
Corporate Governance & Executive
Oral Drug Delivery & Advanced Excipients
UCB’S Vision 3 UCB: Reinventing Itself, Leveraging a Solid Heritage
2004 Annual Report
Corporate Governance and Executive Pay Legislative Landscape and Market Insights (2019)
11/30/20 Index Total (After Close) Constituents 429
Overview Holding Companies
UCB Ventures Appoints Alicia Irurzun-Lafitte As Partner
COVID-19 Resources: Guidance for Chan Researchers Featured News and Announcements COVID Faqs and New Funding Opportunities for T
SPRITAM® Safely and Effectively
P. 1-27 Check out Our Overall Sustainability Performance > P
Annex 4 to the Consultation Document
UCB and Investor Syndicate Led by Novo Seeds Launch Syndesi Therapeutics to Develop Novel Therapeutics for Cognitive Disorders
FTSE Publications
Euro Stoxx® Sustainability Ex Alcohol Gambling Tobacco
Press Release
EUR XINT M G-DM HL Belgium P EUR Index
UCB Announces Launch of Nile AI, Inc., a Digital Health Company Set to Transform the Course of Epilepsy
Febeliec Answer to the Elia Consultation on the Proposal Of
Euronext Brussels Awards 2020
Antihistamines, Minimally Sedating Therapeutic Class Review (TCR)
Climate Risk Disclosure Barometer Study Belgium 2020 Content
EU-Russia Energy Dialogue
Ucb Launches Successful Bond Issue on Nyse Euronext
UCB Integrated Annual Report 2018 3 People Attraction and Recruitment 108
Anti-Epilepsy Drug VIMPAT®, Submission for Supplemental
Analyst Report Bank Degroof
2007 Report to Shareholders and Society 2007 REPORT to SHAREHOLDERS and SOCIETY
UCB Gets Access to Rights for an Antibody Programme from WILEX for Non-Oncology Indications
Press Release